Doxorubicin Hydrochloride Tillomed:

Withdrawal of the marketing authorisation application



Laboratorios Tillomed Spain S.L.U. withdrew its application for a marketing authorisation of Doxorubicin Hydrochloride Tillomed for the treatment of breast and ovarian cancer, multiple myeloma and AIDS-related Kaposi’s sarcoma.

The company withdrew the application on 2 March 2020.

Key facts

Doxorubicin Hydrochloride Tillomed
Product number
International non-proprietary name (INN) or common name
  • doxorubicin
Active substance
  • doxorubicin hydrochloride
Date of withdrawal
Company making the application
Laboratorios Tillomed Spain S.L.U
Withdrawal type
Initial authorisation

Related information on withdrawals

A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

How useful was this page?

Add your rating